## Abstract This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co‐infected with HIV and hepatitis B virus (HBV). A cross‐sectional study of 847 patients with HIV was conducted. Patients provided blood sampl
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B
✍ Scribed by Lucia Taramasso; Patrizia Caligiuri; Antonio Di Biagio; Bianca Bruzzone; Raffaella Rosso; Giancarlo Icardi; Claudio Viscoli
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 68 KB
- Volume
- 83
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Evaluation of resistance pattern in patients with chronic hepatitis B. Retrospective study of hepatitis B virus (HBV) resistance mutations in patients found viraemic after first‐line treatment. HBV viral load was determined by a real‐time polymerase chain reaction and the substitutions in HBV‐DNA were studied by polymerase sequencing test. First line treatment had failed in 12 out of 33 patients (36%) receiving anti‐HBV drugs. The 12 patients with persistent viraemia were all lamivudine (LAM) experienced and 7 had a polymerase sequencing test available. LAM substitution mutations L180M + M204V/I were found in six out of seven cases, with an accompanying V173L mutation in three cases. These mutations were also related with changes in HBsAg. The use of potent drugs in the first line anti‐HBV therapy may reduce the resistance mutations in the future. J. Med. Virol. 83:1905–1908, 2011. © 2011 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract A retrospective review was performed comparing lamivudine‐resistance mutation patterns between patients infected with hepatitis B virus (HBV) with or without human immunodeficiency virus (HIV) co‐infection. Medical records that included a genotypic test of patients infected with HBV and
## Abstract This was an exploratory study to investigate lamivudine‐resistant hepatitis B virus (HBV) strains in selected lamivudine‐naïve HBV carriers with and without human immunodeficiency virus (HIV) co‐infection in South African patients. Thirty‐five lamivudine‐naïve HBV infected patients with
## Abstract HIV infection has a significant impact on the natural progression of liver disease caused by infection with hepatitis B virus (HBV), but its role in the molecular evolution of HBV is unknown. It is difficult to study the molecular evolution of HBV longitudinally considering its genomic
## Abstract Hepatitis B virus (HBV) has been classified into eight genotypes and can be further divided into several subgenotypes that have different geographic distributions. Because of increased human migration, the prevalence of rare subgenotypes is increasing in Japanese patients with acute hep
## Abstract The clinical and cellular interactions between hepatitis B virus (HBV) and hepatitis C virus (HCV) were investigated in patients co‐infected with the human immunodeficiency virus (HIV). One hundred ninety‐nine patients followed for 6 years were evaluated to compare the level of HBV DNA